137 related articles for article (PubMed ID: 11109253)
1. In situ liposomal preparation containing amphotericin B: related toxicity and tissue disposition studies.
Chakraborty KK; Naik SR
Pharm Dev Technol; 2000; 5(4):543-53. PubMed ID: 11109253
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic and hemolytic evaluation of in-situ liposomal preparation containing amphotericin - beta complexed with different chemically modified beta - cyclodextrins.
Chakraborty KK; Naik SR
J Pharm Pharm Sci; 2003; 6(2):231-7. PubMed ID: 12935435
[TBL] [Abstract][Full Text] [Related]
3. Disposition of aerosolized liposomal amphotericin B.
Lambros MP; Bourne DW; Abbas SA; Johnson DL
J Pharm Sci; 1997 Sep; 86(9):1066-9. PubMed ID: 9294824
[TBL] [Abstract][Full Text] [Related]
4. Long-circulating immunoliposomal amphotericin B against invasive pulmonary aspergillosis in mice.
Otsubo T; Maruyama K; Maesaki S; Miyazaki Y; Tanaka E; Takizawa T; Moribe K; Tomono K; Tashiro T; Kohno S
Antimicrob Agents Chemother; 1998 Jan; 42(1):40-4. PubMed ID: 9449258
[TBL] [Abstract][Full Text] [Related]
5. PHARMACOKINETIC STUDIES OF IN-SITU LIPOSOMAL PREPARATION CONTAINING AMPHOTERICIN B COMPLEXED WITH DIFFERENT CHEMICALLY MODIFIED beta-CYCLODEXTRINS.
Chakraborty KK; Naik SR
J Liposome Res; 2001; 11(1):1-14. PubMed ID: 19530915
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.
Lewis RE; Liao G; Hou J; Chamilos G; Prince RA; Kontoyiannis DP
Antimicrob Agents Chemother; 2007 Apr; 51(4):1253-8. PubMed ID: 17261624
[TBL] [Abstract][Full Text] [Related]
7. Amphotericin B-entrapping lipid nanoparticles and their in vitro and in vivo characteristics.
Jung SH; Lim DH; Jung SH; Lee JE; Jeong KS; Seong H; Shin BC
Eur J Pharm Sci; 2009 Jun; 37(3-4):313-20. PubMed ID: 19491021
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary extraction and accumulation of lipid formulations of amphotericin B.
Matot I; Pizov R
Crit Care Med; 2000 Jul; 28(7):2528-32. PubMed ID: 10921589
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.
Olson JA; Adler-Moore JP; Schwartz J; Jensen GM; Proffitt RT
Antimicrob Agents Chemother; 2006 Jun; 50(6):2122-31. PubMed ID: 16723574
[TBL] [Abstract][Full Text] [Related]
10. Biodistribution of amphotericin B when delivered through cholesterol hemisuccinate vesicles in normal and A. fumigatus infected mice.
Saxena S; Ghosh PC
Pharm Res; 2000 Oct; 17(10):1236-42. PubMed ID: 11145229
[TBL] [Abstract][Full Text] [Related]
11. Effect of cholesterol in various liposomal compositions on the in vivo toxicity, therapeutic efficacy, and tissue distribution of amphotericin B.
Ahmad I; Sarkar AK; Bachhawat BK
Biotechnol Appl Biochem; 1990 Oct; 12(5):550-6. PubMed ID: 2288711
[TBL] [Abstract][Full Text] [Related]
12. Liposomal amphotericin-B in the control of experimental aspergillosis in mice: Part I--Relative therapeutic efficacy of free and liposomal amphotericin-B.
Ahmad I; Sarkar AK; Bachhawat BK
Indian J Biochem Biophys; 1989 Dec; 26(6):351-6. PubMed ID: 2698855
[TBL] [Abstract][Full Text] [Related]
13. Hemolytic and antifungal activity of liposome-entrapped amphotericin B prepared by the precipitation method.
Kim JC; Lee EO; Kim JY; Bae SK; Choi TB; Kim JD
Pharm Dev Technol; 1997 Aug; 2(3):275-84. PubMed ID: 9552455
[TBL] [Abstract][Full Text] [Related]
14. The novel lipid delivery system of amphotericin B: drug profile and relevance to clinical practice.
Rust DM; Jameson G
Oncol Nurs Forum; 1998; 25(1):35-48. PubMed ID: 9460772
[TBL] [Abstract][Full Text] [Related]
15. Design of liposomes to improve delivery of amphotericin-B in the treatment of aspergillosis.
Ahmad I; Sarkar AK; Bachhawat BK
Mol Cell Biochem; 1989 Nov 23-Dec 19; 91(1-2):85-90. PubMed ID: 2695834
[TBL] [Abstract][Full Text] [Related]
16. Characterization of amphotericin B liposome formulations.
Manosroi A; Kongkaneramit L; Manosroi J
Drug Dev Ind Pharm; 2004 May; 30(5):535-43. PubMed ID: 15244089
[TBL] [Abstract][Full Text] [Related]
17. Biodistribution and
Iman M; Huang Z; Alavizadeh SH; Szoka FC; Jaafari MR
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630182
[TBL] [Abstract][Full Text] [Related]
18. Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice.
van Etten EW; ten Kate MT; Stearne LE; Bakker-Woudenberg IA
Antimicrob Agents Chemother; 1995 Sep; 39(9):1954-8. PubMed ID: 8540697
[TBL] [Abstract][Full Text] [Related]
19. Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans.
van Etten EW; Otte-Lambillion M; van Vianen W; ten Kate MT; Bakker-Woudenberg AJ
J Antimicrob Chemother; 1995 Apr; 35(4):509-19. PubMed ID: 7628985
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of liposomal amphotericin B with prolonged circulation in blood in treatment of severe pulmonary aspergillosis in leukopenic rats.
Van Etten EW; Stearne-Cullen LE; ten Kate M; Bakker-Woudenberg IA
Antimicrob Agents Chemother; 2000 Mar; 44(3):540-5. PubMed ID: 10681315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
